Drugs / Cadazolid
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02053181 | Aug → Sep 2012 | Clostridium difficile colitis | Actelion | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01222702 | Jan 2011 → Oct 2012 | Clostridium difficile colitis | Actelion | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03105479 | Apr 2017 → Apr 2018 | Clostridium difficile colitis | Actelion | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01987895 | Mar 2014 → Feb 2017 | Clostridium infectious disease | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT01983683 | Dec 2013 → Mar 2017 | Clostridium difficile colitis | Actelion | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cadazolid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01983683 ↗ |
| Known as | ACT-179811 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707376 ↗ |
| Modality | Small molecule | “Cadazolid, a novel fluoroquinolone-oxazolidinone antibiotic” PMID 26248357 ↗ Jul 2015 |
| Route | Oral | “Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration” NCT01222702 ↗ |